Videos

The chief medical officer and head of translational research at Ring Therapeutics discussed research presented at ASGCT 2024.

The cofounder and chief science officer of Longeveron discussed updated data from the phase 2a CLEAR MIND study.

The chief scientific officer of Tome Biosciences discussed the company’s technologies in the context of integrative gene therapy and cell therapy.

The principal investigator at Seattle Children’s Research Institute discussed her lab’s work on using ultrasound mediated gene delivery to target hemophilia A.

The Don and Marilyn Anderson Professor of Oncology at University of Wisconsin – Madison discussed the state of cell and gene therapy development.

The principal investigator at Seattle Children’s Research Institute discussed her lab’s preclinical research with UMGD for the treatment of hemophilia.

The cofounder and chief scientific officer of Mammoth Biosciences discussed the company’s mouse model research on treating hypertriglyceridemia.

The chief medical officer of Cartesian Therapeutics discussed data presented at ASGCT 2024 from a phase 2a study.

The associate professor of medicine at University of Colorado discussed data presented at ASCO 2024.

The chief medical officer at Creyon Bio overviewed the development of an allele-selective TNPO2 protein for a single patient with a de novo pathology.

Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment

The senior researcher at Seattle Children’s discussed the development and validation of A2-CAR-CISC EngTreg cells.

The medical director of clinical development at AskBio discussed setbacks in the phase 1 trial of AB-1002 gene therapy.

The chief scientific officer of Caribou Biosciences discussed the company’s platform for genome editing.

The chairman and chief executive officer of NKGen discussed the new clinical study design for evaluating the NK cell therapy in PD.

The PhD candidate from Lieden University Medical Center and Breakefield Lab at Mass Gen discussed her work presented at the ASGCT 2024 meeting.

The associate professor of medicine at University of Colorado discussed how the field has shifted to support the growing use of CAR Ts and progress to come.

The chairman and chief executive officer of NKGen discussed the mechanism behind the company’s NK cell therapy SNK01 and promising early results in patients with PD.

The professor of internal medicine and pediatrics at National Jewish Health discussed updated data from the phase 1/2 AEROW trial of 4D-710.

The clinical professor of neurology and pediatrics at Keck School of Medicine of USC also discussed current strategies with gene therapy administration.

The chairman and chief executive officer of NKGen discussed the potential of SNK01, the company’s autologous natural killer cell therapy, in treating PD.

The associate professor of medicine at University of Colorado discussed a post hoc analysis study on subgroup analyses of liso-cel response.

The associate professor of neurology at the Cleveland Clinic Lerner Institute discussed the challenges that will need to be overcome to apply gene therapy to a complex neurological disorder like PD.

The senior researcher at Seattle Children’s discussed advantages of engineered Tregs compared with natural Tregs.

The associate professor of neurology at the Cleveland Clinic Lerner Institute pointed out that genetic forms of PD may be the best place to start for new therapeutic research.

The professor in residence for pediatrics at the Sickle Cell Center of Excellence at the University of California discussed gene therapy’s ongoing transformation of the treatment landscape.

The Don and Marilyn Anderson Professor of Oncology at University of Wisconsin – Madison emphasized similar variables in the way of therapy uptake regardless of country.

The cofounder and chief executive officer of Kate Therapeutics discussed research that awarded him an Outstanding New Investigator at the ASGCT 2024 meeting.